Product Data Sheet

Clomiphene citrate

Cat. No.: HY-B0463 CAS No.: 50-41-9

Molecular Formula: C₃₂H₃₆ClNO₈ Molecular Weight: 598.08

Target: Estrogen Receptor/ERR

Pathway: Vitamin D Related/Nuclear Receptor 4°C, sealed storage, away from moisture

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

Storage:

In Vitro DMSO: $\geq 50 \text{ mg/mL} (83.60 \text{ mM})$

H₂O: 1 mg/mL (1.67 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.6720 mL	8.3601 mL	16.7202 mL
	5 mM	0.3344 mL	1.6720 mL	3.3440 mL
	10 mM	0.1672 mL	0.8360 mL	1.6720 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: PBS Solubility: 7.14 mg/mL (11.94 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
- 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.18 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.18 mM); Clear solution
- 4. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.18 mM); Clear solution

BIOLOGICAL ACTIVITY

Clomiphene citrate (Clomifene citrate) is an orally active estrogen-receptor modulator. Clomiphene citrate has anti-cancer Description actixity, induces perturbations during meiotic maturation and cytogenetic abnormalities and ameliorates in managing

psychiatric and cognitive impairment^{[1][2][3]}.

In Vitro Clomiphene citrate (50 µM, 1-30 min) inhibits the viability of PC3 human prostate cancer cells^[1]. Clomiphene citrate (1-5 μ g/mL, 18 h) induces chromosome abnormalities in mouse oocytes^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

 ${\sf Cell\ Viability\ Assay}^{[1]}$

Cell Line:	PC3 human prostate cancer cells	
Concentration:	50 μΜ	
Incubation Time:	1 min, 2 min, 5 min, 10 min, 15 min, 20 min, 30 min	
Result:	Reduced cell viability by 10-50% for 2-15 min in a time-dependent manner.	

In Vivo

Clomiphene citrate (25-100 mg/kg, Intraperitoneal injection, single dose) induces chromosome abnormalities in mouse metaphase II oocytes $^{[2]}$.

Clomiphene citrate (1 mg/kg, Oral, once a day for 15 days) with carvedilol (HY-B0006) has anxiolytic potential and improved cognitive functions in letrozole(HY-14248)-induced polycystic ovary syndrome (PCOS) rats^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female ICR mice ^[2]		
Dosage:	25 mg/kg, 50mg/kg, 100mg/kg		
Administration:	Intraperitoneal injection (i.p.)		
Result:	Resulted in a decrease in the number of ovulated oocytes and a significant increase in hyperploidy at 100 mg/kg.		
Animal Model:	letrozole(HY-14248)-induced PCOS rats ^[3]		
Allillat Model.	tetrozote(111-14240)-induced i COSTats ·		
Dosage:	1 mg/kg		
Administration:	Oral		
Result:	Demonstrated a statistically raised NRF-2 gene expression.		
	Up-regulated expression of NF-кВ.		
	Showed a reversal of the memory defect.		
	Down-regulated of acetylcholine esterase expression.		


CUSTOMER VALIDATION

- J Pharmaceut Biomed. 2020, 113870.
- Biochem Biophys Res Commun. 2020 Feb 19;522(4):862-868.
- Patent. US11696914.
- bioRxiv. 2020 May.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Jiann B P, et al. Effect of clomiphene on Ca2+ movement in human prostate cancer cells [J]. Life Sciences, 2002, 70(26): 3167-3178.



Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 3 of 3 www.MedChemExpress.com